Long-Acting PrEP Status Update

This long-acting PrEP status update is revised on a quarterly basis by AVAC, Secretariat to the Coalition to Accelerate Access to Long-Acting PrEP, to synthesize the current status of long-acting PrEP products. This is done in service to the wider ecosystem. It is not a deliverable of the Coalition nor representative of the views of the individual institutions that make up the Coalition.

Below you will find graphics pertaining to the regulatory approvals, volumes, ongoing and planned implementation science studies, and non-profit prices for currently available long-acting PrEP products—injectable cabotegravir, injectable lenacapavir, and the dapivirine vaginal ring). Visit AVAC’s website for a full suite of LEN-related advocacy tools and resources.

The Pathway to Access and Impact

This graphic outlines the critical steps for rolling out long-acting injectable PrEP products.

Comparing Product Approvals, Volume, Implementation, and Price